TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $49.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Amgen, and Ascendis Pharma. According to TipRanks, Werber has an average return of 24.8% and a 60.48% success rate on recommended stocks.
In addition to TD Cowen, Ultragenyx Pharmaceutical also received a Buy from William Blair’s Sami Corwin in a report issued today. However, on February 4, TipRanks – Google reiterated a Hold rating on Ultragenyx Pharmaceutical (NASDAQ: RARE).
Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.93 million and a GAAP net loss of $180.41 million. In comparison, last year the company earned a revenue of $139.49 million and had a GAAP net loss of $133.52 million
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year. Earlier this month, Howard Horn, the CFO of RARE sold 3,061.00 shares for a total of $72,117.16.
Read More on RARE:
Disclaimer & DisclosureReport an Issue
- Ultragenyx Launches Restructuring Plan to Cut Costs
- Ultragenyx reports Q4 EPS ($1.29), consensus ($1.17)
- Ultragenyx sees FY26 revenue $730M-$760M, consensus $790.67M
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
